bridion174-sugammadex(文件)
【正文】 Robinul) mg/ml SDV $390 Bridion174。18:99. Bridion174。 Sugammadex References 1. 2. Bridion? package insert. Merck. Dec. 2020. 3. Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex ( mg/kg) significantly faster reverses shallow rocuroniuminduced neuromuscular blockade pared with neostigmine (50 181。18:99. ? Sugammadex achieved significantly faster recovery of T4/T1 ratio to pared with neostigmine after neuromuscular block with rocuronium ? Outliers and variability of recovery times were significantly lower following reversal with sugammadex Blobner M, et al. Eur J Anaesthesiol. 2020。 [package insert]. Bridion vs. neostigmine reversal agent for NMB induced by rocuronium or vecuronium at reappearance of T2 (Moderate Blockade) Eur J Anaesthesiol 2020。 [package insert]. Bridion174。 [package insert]. Bridion174。 [package insert]. Bridion174。 Sugammadex Objectives ? At the end of this presentation participants will be able to: 1. Appropriately remend Bridion174。 Sugammadex Manufacturer: Merck FDA Approval Date: December 15, 2020 Bridion174。 Sugammadex Clinical Application
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1